These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17434043)

  • 1. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.
    Fulchiero GJ; Salvaggio H; Drabick JJ; Staveley-O'Carroll K; Billingsley EM; Marks JG; Helm KF
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S65-7. PubMed ID: 17434043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 3. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K; Koike T
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 7. [Proper usage of biologics for treatment of rheumatoid arthritis].
    Murayama M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):894-8. PubMed ID: 19469085
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period.
    Conti F; Scrivo R; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Clin Exp Rheumatol; 2009; 27(3):540-1. PubMed ID: 19604456
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 11. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.
    Chu DH; Van Voorhees AS; Rosenbach M
    Arch Dermatol; 2011 Oct; 147(10):1228-30. PubMed ID: 22006150
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 17. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis.
    Koens L; Senff NJ; Vermeer MH; Ronday HK; Willemze R; Jansen PM
    Acta Derm Venereol; 2009 Nov; 89(6):653-4. PubMed ID: 19997706
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
    Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication].
    Christensen R; Kristensen LE; Geborek P; Danneskiold-Samsøe B; Saxne T; Bliddal H
    Ugeskr Laeger; 2009 Jun; 171(26):2192-4. PubMed ID: 19678436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab-associated multiple sclerosis.
    Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
    J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.